Pressure BioSciences Inc.

Full interview: Pressure BioSciences CEO sees potential opportunity to enter clinical market after recent customer data

Pressure BioSciences Inc (OTCMKTS:PBIO) CEO Ric Schumacher tells Proactive the medical device company's signature Pressure Cycling Technology (PCT) platform has been highlighted by scientists in China and Australia, which Schumacher says could eventually propel the company into the clinical market space.

The two separate cancer research organizations, who are some of Pressure's largest customers, published findings that showcased PCT’s ability to discover biomarkers associated with cancer in tissue samples preserved from biopsies and highlighted its potential as a diagnostic tool.

Quick facts: Pressure BioSciences Inc.

Price: $3.24

Market: OTCQB
Market Cap: $6.28 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pressure BioSciences Inc. named herein, including the promotion by the Company of Pressure BioSciences Inc. in any Content on the Site, the...



Full interview: Pressure BioSciences signs on two more clients for its...

Pressure BioSciences Inc (OTCMKTS:PBIO) CEO Ric Schumacher tells Proactive the medical device company has won two more customers for its water-soluble CBD manufacturing system, the BaroShear K45. Schumacher says one of the company's new customers, privately-held NanoPeak Solutions, will use...

3 weeks, 6 days ago

2 min read